Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids

Firas Hamdan; Erkko Ylösmäki; Jacopo Chiaro; Yvonne Giannoula; Maeve Long; Manlio Fusciello; Sara Feola; Beatriz Martins; Michaela Feodoroff; Gabriella Antignani; Salvatore Russo; Otto Kari; Moon Lee; Petrus Järvinen; Harry Nisen; Anna Kreutzman; Jeanette Leusen; Satu Mustjoki; Thomas G. McWilliams; Mikaela Grönholm; Vincenzo Cerullo

doi:10.1136/jitc-2021-003000

Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids

Firas Hamdan, Erkko Ylösmäki, Jacopo Chiaro, Yvonne Giannoula, Maeve Long, Manlio Fusciello, Sara Feola, Beatriz Martins, Michaela Feodoroff, Gabriella Antignani, Salvatore Russo, Otto Kari, Moon Lee, Petrus Järvinen, Harry Nisen, Anna Kreutzman, Jeanette Leusen, Satu Mustjoki, Thomas G. McWilliams, Mikaela GrönholmVincenzo Cerullo

Research output: Contribution to journal › Article › Scientific › peer-review

Original language	English
Article number	003000
Journal	Journal for Immunotherapy of Cancer
Volume	9
Issue number	8
Number of pages	19
ISSN	2051-1426
DOIs	https://doi.org/10.1136/jitc-2021-003000
Publication status	Published - 2021
MoE publication type	A1 Journal article-refereed

Fields of Science

antibody formation
immunotherapy
oncolytic virotherapy
GAMMA-RS
T-CELLS
ANTIBODY
CANCER
NEUTROPHILS
RECEPTOR
EFFICACY
REPLICATION
BLOCKADE
THERAPY
317 Pharmacy
3122 Cancers
1182 Biochemistry, cell and molecular biology

Access to Document

10.1136/jitc-2021-003000

e003000.fullFinal published version, 4.77 MBLicence: CC BY-NC

Cite this

Hamdan, F., Ylösmäki, E., Chiaro, J., Giannoula, Y., Long, M., Fusciello, M., Feola, S., Martins, B., Feodoroff, M., Antignani, G., Russo, S., Kari, O., Lee, M., Järvinen, P., Nisen, H., Kreutzman, A., Leusen, J., Mustjoki, S., McWilliams, T. G., ... Cerullo, V. (2021). Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids. Journal for Immunotherapy of Cancer, 9(8), Article 003000. https://doi.org/10.1136/jitc-2021-003000

@article{1bb6aa390ef542a29c099d7ed516068e,

title = "Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids",

keywords = "antibody formation, immunotherapy, oncolytic virotherapy, GAMMA-RS, T-CELLS, ANTIBODY, CANCER, NEUTROPHILS, RECEPTOR, EFFICACY, REPLICATION, BLOCKADE, THERAPY, 317 Pharmacy, 3122 Cancers, 1182 Biochemistry, cell and molecular biology",

author = "Firas Hamdan and Erkko Yl{\"o}sm{\"a}ki and Jacopo Chiaro and Yvonne Giannoula and Maeve Long and Manlio Fusciello and Sara Feola and Beatriz Martins and Michaela Feodoroff and Gabriella Antignani and Salvatore Russo and Otto Kari and Moon Lee and Petrus J{\"a}rvinen and Harry Nisen and Anna Kreutzman and Jeanette Leusen and Satu Mustjoki and McWilliams, {Thomas G.} and Mikaela Gr{\"o}nholm and Vincenzo Cerullo",

year = "2021",

doi = "10.1136/jitc-2021-003000",

language = "English",

volume = "9",

journal = "Journal for Immunotherapy of Cancer",

issn = "2051-1426",

publisher = "BMJ PUBLISHING GROUP",

number = "8",

}

Hamdan, F , Ylösmäki, E , Chiaro, J, Giannoula, Y, Long, M, Fusciello, M , Feola, S, Martins, B, Feodoroff, M, Antignani, G , Russo, S , Kari, O, Lee, M, Järvinen, P , Nisen, H , Kreutzman, A, Leusen, J, Mustjoki, S , McWilliams, TG , Grönholm, M & Cerullo, V 2021, 'Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids', Journal for Immunotherapy of Cancer, vol. 9, no. 8, 003000. https://doi.org/10.1136/jitc-2021-003000

Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids. / Hamdan, Firas ; Ylösmäki, Erkko ; Chiaro, Jacopo et al.
In: Journal for Immunotherapy of Cancer, Vol. 9, No. 8, 003000, 2021.

Research output: Contribution to journal › Article › Scientific › peer-review

TY - JOUR

T1 - Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids

AU - Hamdan, Firas

AU - Ylösmäki, Erkko

AU - Chiaro, Jacopo

AU - Giannoula, Yvonne

AU - Long, Maeve

AU - Fusciello, Manlio

AU - Feola, Sara

AU - Martins, Beatriz

AU - Feodoroff, Michaela

AU - Antignani, Gabriella

AU - Russo, Salvatore

AU - Kari, Otto

AU - Lee, Moon

AU - Järvinen, Petrus

AU - Nisen, Harry

AU - Kreutzman, Anna

AU - Leusen, Jeanette

AU - Mustjoki, Satu

AU - McWilliams, Thomas G.

AU - Grönholm, Mikaela

AU - Cerullo, Vincenzo

PY - 2021

Y1 - 2021

KW - antibody formation

KW - immunotherapy

KW - oncolytic virotherapy

KW - GAMMA-RS

KW - T-CELLS

KW - ANTIBODY

KW - CANCER

KW - NEUTROPHILS

KW - RECEPTOR

KW - EFFICACY

KW - REPLICATION

KW - BLOCKADE

KW - THERAPY

KW - 317 Pharmacy

KW - 3122 Cancers

KW - 1182 Biochemistry, cell and molecular biology

U2 - 10.1136/jitc-2021-003000

DO - 10.1136/jitc-2021-003000

M3 - Article

SN - 2051-1426

VL - 9

JO - Journal for Immunotherapy of Cancer

JF - Journal for Immunotherapy of Cancer

IS - 8

M1 - 003000

ER -

Hamdan F , Ylösmäki E , Chiaro J, Giannoula Y, Long M, Fusciello M et al. Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids. Journal for Immunotherapy of Cancer. 2021;9(8):003000. doi: 10.1136/jitc-2021-003000